Cello Group plc (CLL) Receives Buy Rating from N+1 Singer
Cello Group plc (LON:CLL)‘s stock had its “buy” rating restated by equities researchers at N+1 Singer in a note issued to investors on Tuesday. They currently have a GBX 128 ($1.67) price target on the stock, up from their previous price target of GBX 127 ($1.66). N+1 Singer’s target price suggests a potential upside of 19.63% from the company’s previous close.
Other equities analysts have also issued reports about the company. Cenkos Securities Ltd reaffirmed a “buy” rating on shares of Cello Group plc in a research note on Wednesday, September 14th. Peel Hunt reaffirmed a “buy” rating and set a GBX 130 ($1.70) price target on shares of Cello Group plc in a research note on Tuesday, July 26th.
Shares of Cello Group plc (LON:CLL) opened at 106.00 on Tuesday. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00. The stock has a 50 day moving average price of GBX 104.04 and a 200-day moving average price of GBX 97.59. The stock’s market cap is GBX 92.16 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/cello-group-plc-cll-receives-buy-rating-from-n1-singer.html
The business also recently disclosed a dividend, which will be paid on Friday, November 4th. Stockholders of record on Thursday, October 6th will be given a dividend of GBX 1 ($0.01) per share. The ex-dividend date of this dividend is Thursday, October 6th. This represents a dividend yield of 0.94%.
Cello Group plc Company Profile
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.